SCHEMBL2173047

SCHEMBL2173047

Cc1cc(O[C@H]2C[C@H](C(=O)NO)[C@@](C)(C(=O)N3CCN(c4ccccc4)CC3)N(C(=O)O)C2)c2ccccc2n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
ADAM17 P78536 11/20 0.42
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
NCF1 P14598 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
GFER P55789 1/20 0.37
P2RY12 Q9H244 1/20 0.37
ADAM10 O14672 1/20 0.36
ERBB2 P04626 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP9 P14780 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177555 0.89 HCRTR2 (0.38) ALDH1A1ADAM17HCRTR1HCRTR2LMNA
SCHEMBL2172691 0.86 ADAM10 (0.40) ALDH1A1LMNAADAM10ERBB2MMP2
SCHEMBL2174755 0.85 ADAM10 (0.38) ALDH1A1ADAM17HCRTR1HCRTR2LMNA
SCHEMBL2171783 0.84 ADAM10 (0.40) ALDH1A1LMNAADAM10ERBB2MMP2
SCHEMBL2174042 0.84 ADAM10 (0.44) ALDH1A1LMNAADAM10ERBB2MMP2
SCHEMBL2175303 0.84 ADAM10 (0.39) ALDH1A1LMNAADAM10ERBB2MMP2
SCHEMBL2175238 0.84 ADAM10 (0.39) ALDH1A1MAPTLMNAPOLBADAM10
SCHEMBL2176111 0.83 MAPT (0.39) ALDH1A1MAPTHCRTR2LMNAADAM10
SCHEMBL2173584 0.83 ADAM10 (0.37) ALDH1A1LMNAADAM10ERBB2MMP2
SCHEMBL2173465 0.82 ADAM10 (0.38) ALDH1A1LMNAADAM10ERBB2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US claimed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US claimed
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 ALDH1A1 673/4885MAPT 2590/4885MAPK1 1676/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 ALDH1A1 497/4885MAPT 2732/4885MAPK1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.